Citigroup’s Vir Biotechnology VIR Stock Holding History
Bought
Maintained
Sold
Other funds holding VIR
Citigroup's VIR Position: Q3 2026 in Review
Citigroup reduced its Vir Biotechnology (VIR) stake by 65% in Q3 2026, selling an estimated $1.43M and leaving 75,620 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.
Citigroup first reported a position in VIR in Q4 2019 and has held it in 28 quarters since. The position peaked at $11.4M in Q1 2024. 266 funds tracked by Wall St. Rank hold VIR as of Q3 2026.
- Citigroup held 75,620 shares of Vir Biotechnology worth $845K as of Q3 2026.
- Citigroup sold 142,799 Vir Biotechnology shares in Q3 2026, an estimated $1.43M.
- Vir Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3446 holding.
- Citigroup first reported a position in Vir Biotechnology in Q4 2019 and has held it in 28 quarters since.
- Citigroup's Vir Biotechnology position peaked at $11.4M in Q1 2024.
- 266 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.